Researchers wanted to determine if concurrent the development of morbidity issues ( i.e.- myocardial infarction, congestive heart failure, angina, diabetes, stroke, circulation problems, inflammatory bowel disease, or amputation) is associated with treatment regret among men with PSA recurrence following failed primary therapy for prostate cancer.
The researchers evaluated 795 men from the Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry (COMPARE) study who experienced PSA failure. The men who were assessed had a a median of 5.5 (interquartile range 2.8-9.1) years after prostatectomy (n=410), external beam radiation (n=237), brachytherapy (n=124), or primary androgen deprivation (n=24). Multivariable logistic regression was used to determine whether the morbidity level, socio-demographic factors, and other treatment factors were associated with treatment regret, as defined by a validated two-question screen.
1- Of 795 men, 14.8% reported regret. Men with significant morbidity issues were more likely to experience post-therapy bowel toxicity (p=0.029) and urinary problems (p=0.051).
2- On multivariable analysis, significant morbidity